[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-nervous-system-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-nervous-system-diseases":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,77,122,151,185,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":47,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100567749","phase-3-a-phase-3-study-of-ntla-2001-in-attrv-pn-100567749",false,"NCT06672237","A Phase 3 Study of NTLA-2001 in ATTRv-PN","MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)","Inclusion Criteria:\n\n* Diagnosis of ATTRv-PN\n* Karnofsky Performance Status (KPS) ≥ 60\n\nExclusion Criteria:\n\n* Other causes of amyloidosis (amyloidosis caused by non-TTR protein)\n* Other known causes of sensorimotor or autonomic neuropathy\n* Diabetes mellitus\n* New York Heart Association Class III or IV heart failure\n* Liver failure\n* Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisense oligonucleotides (ASOs))\n* Estimated Glomerular Filtration Rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Unable or unwilling to take vitamin A supplementation for the duration of the study\n* History of liver disease","ALL","18 Years","85 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Neuromuscular Disease","Neuromuscular Diseases (NMD)","Neurodegenerative Disease","Neurodegenerative Disease, Hereditary","Neurodegenerative Diseases","Neuromuscular Diseases","Nerve Disorders","Nervous System Disease","Nervous System Diseases","Genetic Disease, Inborn","Amyloidosis, Familial","Amyloidosis, Hereditary","Amyloidosis","Polyneuropathies","Amyloid Neuropathies","Amyloid Neuropathies, Familial","Peripheral Nervous System Disease","Peripheral Nervous System Diseases","Metabolism, Inborn Errors","Metabolic Diseases",[48,39,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63],"TTR","Polyneuropathy","NTLA-2001","ATTR","ATTR-PN","ATTRv-PN","Transthyretin","TTR-mediated amyloidosis","Amyloidosis, hereditary","Amyloidosis, hereditary, transthyretin-related amyloidosis","Transthretin amyloid polyneuropathy","TTR PN","TTR polyneuropathy","nexiguran ziclumeran","nex-z","CRISPR","RECRUITING","2026-04-13",{"date":67,"type":68},"2026-04-16","ACTUAL",{"date":70,"type":68},"2024-11-22",{"date":72,"type":21},"2028-08",{"name":74,"class":75},"Intellia Therapeutics","INDUSTRY",14,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100629468","phase-2-the-effect-of-oral-dlbs1033-in-patients-with-diabetic-polyneuropathy-100629468","NCT07475065","The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy","The Effect of Oral DLBS1033 as Adjuvant Therapy on Inflammatory Biomarkers, Neuroregeneration Biomarkers, and Disease Severity in Patients With Diabetic Polyneuropathy: A Randomized Controlled Trial (An Evaluation of Changes in TCNS, TNF-α, NGF, and Sensory Nerve Conduction Study of the Sural Nerve)","Inclusion Criteria:\n\n* Adults aged 40-60 years diagnosed with diabetic polyneuropathy by a neurologist or neurology resident.\n* Patients with HbA1c levels between 7-10% within the past 30 days.\n* Willing to participate and able to sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, or planning pregnancy.\n* History of other neurological diseases such as stroke, myelopathy, alcoholic neuropathy, or compressive radiculopathy.\n* Significant renal impairment (creatinine \\> 1.5× upper limit of normal), hepatic impairment (SGOT or SGPT \\> 3× upper limit of normal), or severe cardiac disease (NYHA class III-IV heart failure).\n* History of alcohol consumption for ≥ 5 consecutive years.\n* Heavy smoker (Brinkman Index \\> 600).\n* Known allergy or intolerance to DLBS1033.\n* Autoimmune disease, malignancy, or acute and\u002For chronic inflammatory conditions other than diabetic polyneuropathy.\n* Participation in another interventional pharmacological clinical study within 30 days prior to screening.\n* Currently taking anti-inflammatory and\u002For antioxidant medications.","40 Years","60 Years",{"count":87,"type":21},34,[89,24],"PHASE2","This study aims to evaluate whether oral DLBS1033 can improve clinical symptoms and biological markers of nerve damage in adults with diabetic polyneuropathy. The trial enrolls patients with type 2 diabetes who show clinical signs of peripheral nerve injury.\n\nParticipants will receive either DLBS1033 as adjuvant therapy or standard therapy alone for 28 days. The study will compare changes in neuropathy severity (Toronto Clinical Neuropathy Score), inflammatory biomarkers (TNF-α), neuroregeneration biomarkers (Nerve Growth Factor), and sensory nerve conduction parameters of the sural nerve between the two groups. Blood tests, clinical assessments, and nerve conduction studies will be performed at baseline and follow-up visits. Participants will also report any symptoms or adverse events throughout the study.",[92,44,93,94],"Diabetic Polyneuropathy","Peripheral Neuropathy","Diabetes Mellitus",[96,97,98,99,100,101,102,103,104,105,106,107,108,109],"DLBS1033","lumbrokinase","diabetic polyneuropathy","peripheral neuropathy","Toronto Clinical Neuropathy Score","TNF-α","TNF-alpha","Nerve Growth Factor","sural nerve","nerve conduction study","NCS","EMG","ENMG","Electromyography","NOT_YET_RECRUITING","2026-03-13",{"date":113,"type":68},"2026-03-16",{"date":115,"type":21},"2026-03-01",{"date":117,"type":21},"2026-06-30",{"name":119,"class":120},"Universitas Sebelas Maret","OTHER",1,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":121},"100423945","the-effects-of-afo-heel-height-and-stiffness-on-gait-100423945","NCT04800484","The Effects of AFO Heel Height and Stiffness on Gait","AFOHeel","GROUP 1 Patient Inclusion criteria\n\n* Ages: 18-70\n* Daily AFO use to address unilateral, below knee functional deficits that result from limb injury or musculoskeletal disease (e.g. fracture, muscle and\u002For nerve injury, ankle arthritis)\n* Greater than 2 weeks using their current AFO\n* Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.)\n* Ability to walk at a slow to moderate pace\n* AFO fits into traditional footwear\n* Able to read and write in English and provide written informed consent\n\nGROUP 1 Patient Exclusion criteria\n\n* Pain \\> 6\u002F10 while walking during testing or an increase in pain during testing of \\> 2\u002F10.\n* Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity).\n* Disorder or disease that affects peripheral nerve function (e.g. diabetes, Charcot Marie Tooth).\n* Limited contralateral lower limb function due to injury or neurological\u002Fmusculoskeletal disorder.\n* Use of a hinged\u002Farticulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist\u002Fstop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot.\n* Use of an AFO that crosses the knee (Knee brace)\n* Insufficient space in shoe to accommodate the tallest heel wedge and their AFO\n* Visual or hearing impairments that limit walking ability or could limit the ability to comply with instructions given during testing\n* Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study.\n* Body Mass index \\> 40.\n\nGROUP 2 Patient Inclusion Criteria\n\n* Ages: 18-70\n* Daily AFO use to address below knee functional deficits that result from disease involving the peripheral nervous system (e.g. Charcot Marie Tooth, Multiple Sclerosis, diabetes)\n* Greater than 2 weeks using their current AFO (unilateral or bilateral)\n* Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.)\n* AFO fits into traditional footwear\n* Ability to walk at a slow to moderate pace\n* Able to read and write in English and provide written informed consent\n\nGROUP 2 Patient Exclusion Criteria\n\n* Pain \\> 6\u002F10 while walking or an increase in pain during testing of \\> 2\u002F10\n* Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity)\n* Limited function due to limb injury (e.g. fracture, muscle and\u002For nerve injury)\n* Use of a hinged\u002Farticulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist\u002Fstop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot.\n* Use of an AFO that crosses the knee (Knee brace)\n* Insufficient space in shoe to accommodate the tallest heel wedge and their AFO\n* Visual or hearing impairment that limit walking ability or limit the ability to comply with instructions given during testing\n* Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study\n* Body Mass index \\> 40.","70 Years",{"count":131,"type":21},40,[133],"NA","The proposed study evaluates the effect of ankle foot orthosis (AFO) heel height and stiffness on the forces and motion of the lower limb during over-ground walking in individuals who use an AFO for daily walking. Previous studies suggest that heel height and stiffness effect limb loading, but these data and the analysis techniques applied are limited. In this study, heel cushions with different height and stiffness's (4 conditions) will be placed in participants shoes and they will walk at controlled and self-selected speeds. Participants will also walk with their AFO as configured prior to enrollment, and with no AFO if possible. The proposed study will provide evidence that can be used by clinicians and researchers to align braces that most effectively improve function during every-day walking.",[136,137,44],"Musculoskeletal Injury","Musculoskeletal Diseases",[139,140,141],"Gait Analysis","Ankle Foot Orthosis","Biomechanics","2025-12-29",{"date":144,"type":68},"2025-12-31",{"date":146,"type":68},"2019-11-07",{"date":148,"type":21},"2027-01-01",{"name":150,"class":120},"University of Iowa",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":174,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":121},"100498995","music-therapy-in-complex-specialist-neurorehabilitation-100498995","NCT05777499","MUSic Therapy In Complex Specialist Neurorehabilitation","Pilot Study to Evaluate MUSic Therapy in Complex Specialist Neurorehabilitation","MUSICS","Inclusion Criteria:\n\n* Age 16 years or above.\n* Clinical diagnosis of a neurological injury involving the brain, spinal cord, and\u002For peripheral nerves, sustained during the current hospital admission.\n* Participant has complex rehabilitation needs warranting admission to a specialist neurorehabilitation unit.\n* Willing and able to provide written informed consent. If the participant is unable to demonstrate sufficient mental capacity to provide informed consent, the multidisciplinary team will liaise with the participant to identify a suitable consultee to determine suitability to participate in the study in their best interests.\n\nExclusion Criteria:\n\n* Participant is medically unstable or excessively drowsy, and is unexpected to be able to tolerate an intensive rehabilitation program.\n* Participant is expected to be discharged from hospital before 10 weeks.\n* Concurrent and\u002For recent involvement in other research that is likely to interfere with the intervention within the last 3 months of study enrolment.","16 Years","80 Years",{"count":162,"type":21},75,[133],"Aim: Investigate whether patients undergoing specialist rehabilitation after complex neurological injury show different functional outcomes if music therapy is included in their rehabilitation program compared to usual care.\n\nBackground: Patients with complex needs following a brain, spinal cord, and\u002For peripheral nerve injury often require a period of specialist neurorehabilitation. This involves multiple therapy disciplines, led by a Consultant in Rehabilitation Medicine, Neurology, or Neuropsychiatry. Although music therapy is suggested to enhance neuroplasticity and recovery in patients with brain injury, it is not routinely commissioned in clinical care due to a lack of supportive evidence.\n\nHypothesis: Patients undergoing music therapy in addition to complex specialist rehabilitation show better functional outcomes compared to usual care.\n\nNumber of participants: 75, aged 16-80 years. Methods: Patients undergo baseline assessments and are randomised to MUSIC or CONTROL Therapy. Both arms receive 1-3 additional therapy sessions per week, matched for duration and number, total 15 hours. After approximately 10-weeks intervention, assessments are repeated. All participants then have access to music therapy until they are discharged from Neurorehabilitation Unit (NRU), with additional qualitative data collection using semi-structured interviews, field notes, staff reports, staff stress surveys, and broader ecological observations.\n\nDuration for Participants: From consent to discharge from NRU. Primary Outcome: Change in Functional Independence Measure+Functional Assessment Measure (FIM+FAM), Northwick Park Dependency Scale (NWPDS), and Barthel Activities of Daily Living pre and post 15 hours intervention.\n\nSecondary Outcome: Change in quality of life (Flourishing Scale), psychological distress (Hospital Anxiety and Depression Scale, Depression Intensity Scale Circles), social interaction (Sickness Impact Profile Social Interaction Subscale), well-being (WHO Well-Being Index), and communication (Communication Outcomes After Stroke Scale), pre and post 15 hours intervention. Mean difference in well-being (WHO Well-Being Index) throughout the intervention period between music therapy and control therapy groups. Mean difference in post-intervention pain and mood visual analogue scores between music therapy and control therapy groups.",[166,167,168,169,170,171,172,173,44],"Stroke","Subarachnoid Hemorrhage","Traumatic Brain Injury","Tumor, Brain","Autoimmune Diseases","Meningitis\u002FEncephalitis","Acquired Brain Injury","Spinal Cord Injuries",[175],"Neurological injury","2024-10-21",{"date":178,"type":68},"2024-10-23",{"date":180,"type":68},"2023-06-05",{"date":182,"type":21},"2025-10",{"name":184,"class":120},"University College, London",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100328479","walking-ankle-robot-for-foot-drop-in-aging-and-disabled-populations-a-demonstration-project-100328479","NCT03556709","Walking Ankle Robot for Foot Drop in Aging and Disabled Populations: A Demonstration Project","Inclusion Criteria:\n\n1. Men and women, aged 18 to 88 years\n2. Chronic foot drop and ankle weakness in one leg from a peripheral nervous system injury due to a neuromuscular or orthopedic injury\n3. Ability to walk 10 meters and arise from a chair with no human assistance (but usage of usual assistive device\\[s\\] is permitted)\n\nExclusion Criteria:\n\n1. Cardiac history of (a) unstable angina; (b) recent (less than 3 months) myocardial infarction, congestive heart failure (NYHA category II); and\u002For (c) hemodynamically significant valvular dysfunction\n2. Hypertension that is a contraindication for a bout of walking training (greater than 160\u002F100 mmHg on two assessments)\n3. Medical history of (a) recent hospitalization (less than 3 months) for severe medical disease; (b) symptomatic peripheral arterial occlusive disease; (c) orthopedic or chronic pain conditions that significantly alter gait function; (d) pulmonary or renal failure; and\u002For (e) active cancer\n4. Current participation in orthopedic or rehabilitation medical programs\n5. Active deep venous thrombosis\n6. Distal paretic leg skin lesions, infections, or soft tissue inflammation","88 Years",{"count":193,"type":21},100,[133],"The purpose of this research study is to test the utility of an ankle robot, when used during treadmill walking, in people with ankle weakness and foot drop from a peripheral nervous system injury due to neuromuscular or orthopedic injury.",[197,44,198,199],"Foot Drop","Gait Disorders, Neurologic","Mobility Limitation","2018-06-04",{"date":202,"type":68},"2018-06-14",{"date":204,"type":21},"2018-08-01",{"date":206,"type":21},"2028-12-31",{"name":208,"class":209},"Baltimore VA Medical Center","FED",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":191,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":121},"100326481","seated-ankle-robot-for-foot-drop-in-aging-and-disabled-populations-a-demonstration-project-100326481","NCT03530592","Seated Ankle Robot for Foot Drop in Aging and Disabled Populations: A Demonstration Project","Inclusion Criteria:\n\n1. Men and women, aged 18 to 88 years\n2. Chronic foot drop and ankle weakness in one leg from a peripheral nervous system injury due to a neuromuscular or orthopedic injury\n3. Ability to walk 10 meters and arise from a chair with no human assistance (but usage of usual assistive device\\[s\\] is permitted)\n\nExclusion Criteria:\n\n1. Medical history that would preclude participation in low-intensity seated robotic-assisted rehabilitation\n2. Current participation in orthopedic or rehabilitation medical programs\n3. Active deep venous thrombosis\n4. Distal paretic leg skin lesions, infections, or soft tissue inflammation",{"count":193,"type":21},[133],"The purpose of this research study is to test the utility of an ankle robot in people with ankle weakness and foot drop from a peripheral nervous system injury due to neuromuscular or orthopedic injury.",[44,198,197,199],"2018-05-08",{"date":222,"type":68},"2018-05-21",{"date":224,"type":21},"2018-06-01",{"date":206,"type":21},{"name":208,"class":209}]